

Aimmune Therapeutics, Inc.

Form 3

August 05, 2015

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104Expires: January 31,
2005Estimated average
burden hours per
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *Â Longitude Capital Partners II,
LLC

(Last) (First) (Middle)

800 EL CAMINO
REAL,Â SUITE 220

(Street)

MENLO PARK,Â CAÂ 94025

(City) (State) (Zip)

2. Date of Event Requiring
Statement(Month/Day/Year)
08/05/20153. Issuer Name **and** Ticker or Trading Symbol
Aimmune Therapeutics, Inc. [AIMT]4. Relationship of Reporting
Person(s) to Issuer

(Check all applicable)

☐ Director ☒ 10% Owner
☐ Officer ☐ Other
(give title below) (specify below)5. If Amendment, Date Original
Filed(Month/Day/Year)6. Individual or Joint/Group
Filing(Check Applicable Line)
☐ Form filed by One Reporting
Person
☒ Form filed by More than One
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)4. Nature of Indirect Beneficial
Ownership
(Instr. 5)Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security
(Instr. 4)2. Date Exercisable and
Expiration Date
(Month/Day/Year)Date
ExercisableExpiration
Date3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)

Title

Amount or
Number of4. Conversion
or Exercise
Price of
Derivative
Security5. Ownership
Form of
Derivative
Security:
Direct (D)6. Nature of Indirect
Beneficial Ownership
(Instr. 5)

Edgar Filing: Aimmune Therapeutics, Inc. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Series A Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	3,873,530	\$ 0	I	By: Longitude Venture Partners II, L.P. (3)
Series B Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	3,248,600	\$ 0	I	By: Longitude Venture Partners II, L.P. (3)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Longitude Capital Partners II, LLC 800 EL CAMINO REAL SUITE 220 MENLO PARK, CA 94025	Â	Â X	Â	Â
Tammenoms Bakker Juliet C/O LONGITUDE CAPITAL PARTNERS II, LLC 800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025	Â	Â X	Â	Â
Longitude Venture Partners II, L.P. 800 EL CAMINO REAL SUITE 220 MENLO PARK, CA 94025	Â	Â X	Â	Â
ENRIGHT PATRICK G C/O LONGITUDE CAPITAL PARTNERS II, LLC 800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025	Â X	Â X	Â	Â

Signatures

LONGITUDE CAPITAL PARTNERS II, LLC, a Delaware limited liability company, By: /s/ Patrick G. Enright, Managing Member	08/05/2015
____Signature of Reporting Person	Date
LONGITUDE VENTURE PARTNERS II, L.P., By: Longitude Capital Partners II, LLC, a Delaware limited liability company, Its General Partner, By: /s/ Patrick G. Enright, Managing Member	08/05/2015
____Signature of Reporting Person	Date
/s/ Patrick G. Enright	08/05/2015
____Signature of Reporting Person	Date
/s/ Julieta Tammenoms Bakker	08/05/2015
____Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically convert into shares of Issuer's Common Stock on a 1:1 basis immediately prior to the completion of Issuer's initial public offering.
- (2) The expiration date is not relevant to the conversion of these securities.

This report is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Julieta Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital II as general partner of Longitude Venture II

- (3) maybe deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are each managing members of Longitude Capital II and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by Reporting Persons. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.